Boehringer strikes $7.4 billion cancer deal with Sino Biopharma
Boehringer strikes $7.4 billion cancer deal with Sino Biopharma
Boehringer strikes $7.4 billion cancer deal with Sino Biopharma
Key points
اہم نکات
मुख्य बातें
- Germany's Boehringer Ingelheim will pay $358 million upfront to China's Sino Biopharma for an option and licence deal covering six early-stage cancer programmes, five from its LaNova unit and one from Beijing Tide.
- Sino could receive up to $7 billion more in milestone payments plus royalties if the antibody-drug conjugate and T-cell engager treatments reach the market.
- Sino will lead early development, and Boehringer can then take exclusive rights, worldwide for two programmes and outside China for the other four.
- Germany's Boehringer Ingelheim will pay $358 million upfront to China's Sino Biopharma for an option and licence deal covering six early-stage cancer programmes, five from its LaNova unit and one from Beijing Tide.
- Sino could receive up to $7 billion more in milestone payments plus royalties if the antibody-drug conjugate and T-cell engager treatments reach the market.
- Sino will lead early development, and Boehringer can then take exclusive rights, worldwide for two programmes and outside China for the other four.
- Germany's Boehringer Ingelheim will pay $358 million upfront to China's Sino Biopharma for an option and licence deal covering six early-stage cancer programmes, five from its LaNova unit and one from Beijing Tide.
- Sino could receive up to $7 billion more in milestone payments plus royalties if the antibody-drug conjugate and T-cell engager treatments reach the market.
- Sino will lead early development, and Boehringer can then take exclusive rights, worldwide for two programmes and outside China for the other four.
Germany's Boehringer Ingelheim will pay $358 million upfront to China's Sino Biopharma for an option and licence deal covering six early-stage cancer programmes, five from its LaNova unit and one from Beijing Tide. Sino could receive up to $7 billion more in milestone payments plus royalties if the antibody-drug conjugate and T-cell engager treatments reach the market. Sino will lead early development, and Boehringer can then take exclusive rights, worldwide for two programmes and outside China for the other four.
Germany's Boehringer Ingelheim will pay $358 million upfront to China's Sino Biopharma for an option and licence deal covering six early-stage cancer programmes, five from its LaNova unit and one from Beijing Tide. Sino could receive up to $7 billion more in milestone payments plus royalties if the antibody-drug conjugate and T-cell engager treatments reach the market. Sino will lead early development, and Boehringer can then take exclusive rights, worldwide for two programmes and outside China for the other four.
Germany's Boehringer Ingelheim will pay $358 million upfront to China's Sino Biopharma for an option and licence deal covering six early-stage cancer programmes, five from its LaNova unit and one from Beijing Tide. Sino could receive up to $7 billion more in milestone payments plus royalties if the antibody-drug conjugate and T-cell engager treatments reach the market. Sino will lead early development, and Boehringer can then take exclusive rights, worldwide for two programmes and outside China for the other four.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।